Montpellier, France

Montpellier University

umontpellier.fr
Montpellier, France

The University of Montpellier was a French university in Montpellier Hérault, in Languedoc-Roussillon region in south-east France. Its present-day university legacy has been renamed and is currently known as the University of Montpellier 1, Montpellier 2 University and Paul Valéry University, Montpellier III until 2015 when l'université de Montpellier was created a second time. Moreover, the prestigious and famous secondary high-school Lycée Joffre is also a direct heir from the outstanding Montpellier University system. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Montpellier University, French National Center for Scientific Research and French National Institute for Agricultural Research | Date: 2017-05-17

The present invention relates to the use of a biopolymer as a sensitive material in a dielectric gas sensor for water vapor, carbon dioxide, and/or ethanol.


The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a follicular fluid sample.


It comprises new systematic procedures for filtering synchronization data (raw data: tap times and sound/musical beat reference times) in order to obtain accurate and reliable measures of synchronization accuracy and variability (or consistency). The procedures detailed are used to provide reliable synchronization data that can be used to compute measures of synchronization accuracy and variability based on linear statistics or circular statistics. These procedures are particularly appropriate for analyzing synchronization performance in individuals with rhythmic disorders.


Patent
Montpellier University | Date: 2017-03-01

The present invention relates to a compound of formula (I) wherein: - i is 0 or 1; j is 0 or 1; k is 0 or 1; - R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; - R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; - R3 is H and k=0 when j=1; or, when j=0, R3 is -C(O)R or -L-C(O)R; - L, U and L are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.


Patent
Agv Discovery, French Institute of Health, Medical Research, French National Center for Scientific Research and Montpellier University | Date: 2017-05-24

The present invention concerns a compound of formula (I):


The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein i represent the regression coefficient reference value for the gene Gi and Ci = 1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci = -1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSR or concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMSR.


The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and devices for determining the quality of an embryo. More specifically, the present invention relates to the use of three dimensional reconstructions for determining the quality of an embryo.


Patent
Montpellier University and French National Center for Scientific Research | Date: 2017-05-31

The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein i represent the regression coefficient reference value for the gene Gi and Ci = 1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci = -1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSR or concluding that the patient will not respond to the treatment when the DNARS score is lower than the predetermined reference value DNARSR.


The present invention relates to methods for the intercellular transfer of isolated mitochondria in recipient cells. In particular, the present invention relates to a method for the intercellular transfer of an amount of mitochondria isolated from a population of donor cells into a population of recipient cells comprising the step of i) centrifuging the population of recipient mammalian cells in presence of the isolated mitochondria at centrifugation force ranging from 1000g to a 2000g at a temperature ranging from 1C to 8C and for a time ranging from 5min to 30min, ii) resting the centrifuged cells at a temperature ranging from 30C to 40C for a time ranging from 90min to 180min, and iii) repeating the cycling of steps i) and ii) for a sufficient number of times for reaching transfer efficiency.


Patent
Montpellier University | Date: 2017-05-17

The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.

Loading Montpellier University collaborators
Loading Montpellier University collaborators